SENSAN BIOSCIENCES | Recipient of the SCDM 2026 Innovation Award for Innovator Start-up of the Year
SignalAI™: Transforming Clinical Data into Intelligent Decisions
Solution overview
SENSAN BIOSCIENCES received the SCDM 2026 Innovation Award for Innovator Start-up of the Year for its innovative approach to modernizing Clinical Data Management through SignalAI™, an AI-powered Clinical Data Science platform designed to connect clinical data, automate review workflows, and translate complex datasets into actionable intelligence.
SignalAI™ brings together clinical data integration, analytics, predictive modeling, automated review, and AI-enabled signal detection within a connected intelligence framework. Designed to support Clinical Data Managers and cross-functional clinical research teams, the platform helps transform traditional, listing-driven data review into a more proactive, risk-informed approach to clinical trial oversight.
The challenge
Clinical trials generate vast amounts of data across Electronic Data Capture (EDC), electronic clinical outcome assessments (eCOA), laboratory systems, and other clinical technology platforms. However, these data sources often operate independently, creating fragmented views of trial performance and data quality.
Traditional CDM workflows rely heavily on manual listing extraction, repetitive review, reconciliation, discrepancy management, and follow-up. These activities consume valuable specialist capacity and can make it difficult to recognize emerging patterns across datasets or prioritize issues requiring timely investigation.
As clinical trials become increasingly complex, the industry needs solutions that go beyond faster data cleaning. It needs connected clinical intelligence that helps teams understand what has happened, identify emerging signals, and determine where focused review and intervention may be needed.
The innovation
SignalAI™ was developed by combining deep Clinical Data Management knowledge with data engineering, analytics, programming, predictive modeling, and workflow automation. Its architecture connects clinical data with analytical capabilities and operational processes, enabling information to be evaluated in context rather than as isolated records.
The platform supports workflows involving data quality review, dosing-related monitoring, discrepancy identification, risk indicators, and prioritization of CDM activities. Configurable dashboards provide operational visibility, while AI-enabled analytics help identify patterns and potential signals for human assessment.
What differentiates SignalAI™ is its focus on connecting intelligence to real clinical workflows. Rather than treating AI as a standalone feature or dashboard, the platform brings together data integration, analytical models, automated processes, and human-in-the-loop review to support practical decision-making.
This approach reflects a broader vision for clinical data innovation: technology should not simply process more data, but help professionals understand relationships, recognize potential risks, and direct their expertise toward the issues that matter most. Human judgment, clinical context, and accountability remain central to evaluating signals and determining appropriate action.
Impact and results
SignalAI™ has been implemented in an active clinical development project, demonstrating its application beyond a conceptual prototype. In a dosing-review use case, reported results included a 45% reduction in manual review effort, 30% faster turnaround for dosing-related discrepancies, and identification of missed-dose events within 24 hours.
These results demonstrate the potential of connected data intelligence to reduce repetitive review activities, accelerate follow-up, and improve prioritization. By helping teams focus on relevant signals and exceptions, SignalAI™ supports more effective use of specialist resources while strengthening operational visibility and oversight.
Looking ahead
SENSAN BIOSCIENCES envisions SignalAI™ contributing to a future in which Clinical Data Management evolves from a predominantly reactive review function into a connected, intelligence-driven discipline.
Future development will focus on expanding clinical system integrations, advancing agentic AI workflows, strengthening explainability and traceability, and supporting scalable adoption across diverse clinical technology environments.
The ambition is not to replace clinical expertise with automation, but to amplify it. By connecting data, technology, and human judgment, SignalAI™ aims to help clinical research teams move beyond reviewing individual data points toward understanding the signals that inform better decisions.
The future of Clinical Data Management will be defined not simply by how efficiently we process data, but by how intelligently we connect it, interpret it, and act upon it.
Meet the Spokesperson

RISHI RAJ IIMK, CCDS
Manager – Strategic Partnerships & Clinical Innovation
SENSAN BIOSCIENCES.
Rishi Raj is a Clinical Data Management and analytics professional with over a decade of experience across clinical research, data management, analytics, and technology-driven innovation. He currently leads Strategic Partnerships & Clinical Innovation at SENSAN BIOSCIENCES, where he focuses on modernizing clinical data management through automation, Agentic AI, advanced analytics, and intelligent data workflows.
Rishi has hands-on experience across the clinical data lifecycle, including eCRF design, database development, edit checks, data review, query management, reconciliation, data cleaning, and database lock. He leverages technologies including Medidata Rave, SQL, R, SAS, Power BI, Tableau, and Spotfire to transform clinical data into actionable insights.
His work focuses on developing scalable data pipelines, AI-enabled clinical data review solutions, predictive analytics, and centralized monitoring approaches that enable more proactive and efficient clinical trial oversight. He is particularly passionate about bridging Clinical Data Management, Data Science, and AI to accelerate data-driven decision-making and modernize clinical trial execution.
As an innovation leader, Rishi is focused on translating emerging technologies into practical, scalable solutions that improve data quality, operational efficiency, and clinical decision-making.






